search
Back to results

Effectiveness of Smartconsent in Improving Understanding of Informed Consent (SMARTCONSENT)

Primary Purpose

Benign Prostatic Hyperplasia

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Smartconsent application
Control group
Sponsored by
Bioaraba Health Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Benign Prostatic Hyperplasia

Eligibility Criteria

50 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • Patients willing to receive information via tablet.
  • Patients who know and can read.

Exclusion Criteria:

  • Not applicable

Sites / Locations

  • Imanol Merino
  • Bioaraba Health Research Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

smartconsent group

control group

Arm Description

Intervention group: : the principal investigator upon receiving the tablet enters with his/her user and password, registers his/her signature, selects the patient (anonymized), selects the intervention and then the tablet will be given to the patient and he/she will be instructed to follow the indications in order to be able to project the video and digitally sign the informed consent.

Control group: The informed consent paper document (official format) will be printed with the patient's name, signed by the physician (principal investigator) and given to the patient to read and sign.

Outcomes

Primary Outcome Measures

Score in the Multiple choice test questionnaire
Specifically designed for each type of procedure, following the recommendations proposed by Kehoe, Jerard and Fathelrahman et al. and developed on the basis of the information to be provided in an informed consent form, with 4 response options and only one correct answer

Secondary Outcome Measures

Satisfaction with the informed consent proccess
based on three ad hoc designed items: Each item will be scored on a lipo Likert scale with 5 response options.
Ability to complete the informed consent form
Without the need for additional information from the healthcare professional.
Time required to complete the informed consent process (MIN).
The Smartphone stopwatch of the researchers participating in the study will be used for this purpose
Overall satisfaction with the informed consent process,
Through a three-item test, developed ad hoc by a group of researchers to assess satisfaction in a study with similar characteristics to ours.
Score in the System Usability Scale
In the SMARTCONSENT group only. he average System Usability Scale score is 68. If your score is under 68, then there are probably serious problems with your website usability which you should address. If your score is above 68, then you can relax a little bit.

Full Information

First Posted
April 20, 2021
Last Updated
July 14, 2022
Sponsor
Bioaraba Health Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT04856943
Brief Title
Effectiveness of Smartconsent in Improving Understanding of Informed Consent
Acronym
SMARTCONSENT
Official Title
Evaluation of the Effectiveness of Smartconsent to Improve Understanding of Informed Consent in Prostate Laser Enucleation Procedures
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Completed
Study Start Date
December 31, 2021 (Actual)
Primary Completion Date
December 31, 2021 (Actual)
Study Completion Date
December 31, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bioaraba Health Research Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The general objective of the study is to assess whether the new smartconsent tool improves patients' understanding of the intervention to be performed, compared to standard practice. A randomized clinical trial will be conducted in 50 patients who will undergo LASER PROSTATIC ENUCLEATION.
Detailed Description
Male patients aged between 50 and 70 years, belonging to the Hospital Universitario Araba who are going to undergo PROSTATIC LASER ENUCLEATION, and who attend urology consultation between December 2019 and December 2020, and who meet the inclusion criteria and none of the exclusion criteria. Inclusion criteria: Patients willing to receive information via tablet. Patients who know how to and can read. Exclusion criteria: -Not applicable. Main variable: score on the Multiple choice test questionnaire (designed specifically for each type of procedure, following the recommendations proposed by Kehoe, Jerard and Fathelrahman et al. and developed on the basis of the information that an informed consent should provide (1, 2), with 4 response options and only one correct answer. An average score will be calculated for each patient. This test evaluates the comprehension of the information provided through the informed consent.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Benign Prostatic Hyperplasia

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
52 (Actual)

8. Arms, Groups, and Interventions

Arm Title
smartconsent group
Arm Type
Experimental
Arm Description
Intervention group: : the principal investigator upon receiving the tablet enters with his/her user and password, registers his/her signature, selects the patient (anonymized), selects the intervention and then the tablet will be given to the patient and he/she will be instructed to follow the indications in order to be able to project the video and digitally sign the informed consent.
Arm Title
control group
Arm Type
Placebo Comparator
Arm Description
Control group: The informed consent paper document (official format) will be printed with the patient's name, signed by the physician (principal investigator) and given to the patient to read and sign.
Intervention Type
Procedure
Intervention Name(s)
Smartconsent application
Intervention Description
Patients asigned to smartconsent group will sign informed consent through a Tablet.
Intervention Type
Other
Intervention Name(s)
Control group
Intervention Description
Patient asigned to control group will sing the informed consent in papel, as it is performed in clinical practice
Primary Outcome Measure Information:
Title
Score in the Multiple choice test questionnaire
Description
Specifically designed for each type of procedure, following the recommendations proposed by Kehoe, Jerard and Fathelrahman et al. and developed on the basis of the information to be provided in an informed consent form, with 4 response options and only one correct answer
Time Frame
At the recruitment moment
Secondary Outcome Measure Information:
Title
Satisfaction with the informed consent proccess
Description
based on three ad hoc designed items: Each item will be scored on a lipo Likert scale with 5 response options.
Time Frame
At the recruitment moment
Title
Ability to complete the informed consent form
Description
Without the need for additional information from the healthcare professional.
Time Frame
At the recruitment moment
Title
Time required to complete the informed consent process (MIN).
Description
The Smartphone stopwatch of the researchers participating in the study will be used for this purpose
Time Frame
At the recruitment moment
Title
Overall satisfaction with the informed consent process,
Description
Through a three-item test, developed ad hoc by a group of researchers to assess satisfaction in a study with similar characteristics to ours.
Time Frame
At the recruitment moment
Title
Score in the System Usability Scale
Description
In the SMARTCONSENT group only. he average System Usability Scale score is 68. If your score is under 68, then there are probably serious problems with your website usability which you should address. If your score is above 68, then you can relax a little bit.
Time Frame
At the recruitment moment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Patients willing to receive information via tablet. Patients who know and can read. Exclusion Criteria: Not applicable
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
IMANOL MERINO
Organizational Affiliation
Bioaraba Health Research Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Imanol Merino
City
Vitoria Gasteiz
State/Province
Alava
ZIP/Postal Code
01003
Country
Spain
Facility Name
Bioaraba Health Research Institute
City
Vitoria-gasteiz
State/Province
Alava
ZIP/Postal Code
01009
Country
Spain

12. IPD Sharing Statement

Learn more about this trial

Effectiveness of Smartconsent in Improving Understanding of Informed Consent

We'll reach out to this number within 24 hrs